in cigarette smoke is an important exogenous risk factor for malignant transformation of BECs. Thus, an important endogenous risk factor is likely to be the capacity of BECs to metabolize nitrosamines. Among the cytochrome P450 enzymes capable of metabolizing nitrosamines, CYP2A6, CYP2E1 and CYP2B6 are expressed in BECs. In this study, we used quantitative RT-PCR to evaluate expression of CYP2A6 and CYP2E1 in primary human BECs from 12 non-smokers and eight smokers. CYP2A6 was expressed in 20/20 cases and quantifiable in 18/20 cases, with a mean level of 580 mRNA/10 6 β-actin mRNA. CYP2E1 expression was observed in 9/20 cases, but in all cases it was expressed at levels below our limit of quantification (10 mRNA/10 6 β-actin mRNA). There was significant (P < 0.05) 20-fold inter-individual variation in expression of CYP2A6. Further, the mean level of CYP2A6 among smokers (260 mRNA/10 6 β-actin mRNA) was significantly lower than among non-smokers (740 mRNA/10 6 β-actin mRNA). It is hypothesized that: (i) inter-individual variation in CYP2A6 gene expression may contribute to inter-individual variation in risk for bronchogenic carcinoma; (ii) smoking may reduce the level of expression of CYP2A6 in the BECs of some individuals; and (iii) CYP2A6 is more important than CYP2E1 for metabolic activation of nitrosamines in bronchial epithelial cells.
Inter-individual variation in risk for bronchogenic carcinoma is determined by both exogenous and endogenous risk factors. Inhalation of carcinogens and procarcinogens is an important exogenous risk factor. The procarcinogen nitrosamines, NЈ-nitrosonornicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone confer a significant fraction of the carcinogenicity in tobacco smoke (1) . An important endogenous risk factor is the relative expression by bronchial epithelial cells (BECs) of xenobiotic metabolizing enzymes (XME) that metabolically activate nitrosamine carcinogens. The cytochrome P450 (CYP) enzymes CYP1A2, CYP2A6, CYP3A5, CYP2B6 [formerly CYP2B7 (2) ], CYP2E1 and CYP2D6 have all been reported to metabolize nitrosamines (3) . The genes for the CYP2A6, CYP2B6 and CYP2E1 enzymes are expressed in BECs (4) and, of these enzymes, CYP2A6 has the highest specific activity for nitrosamines (5) . Quantification of CYP2B6 expression in BECs has been reported previously (6) . In this study, the goal was to determine the relative level of mRNA expression of CYP2A6 and CYP2E1 among a group of smokers and non-smokers.
Primary human BECs were obtained through bronchial brush biopsy from 12 non-smoker and eight smoker healthy volunteers as previously reported (6) . Informed consent was obtained from each volunteer. Demographic data for the volunteers is provided in Table I . Subject numbers correspond to those published in Willey et al. (6) . Additional subjects were numbered in order of their acquistion. Cells were recovered from the bronchial brush into 0.9% NaCl solution on ice and pelleted.
Total RNA was extracted with TriReagent (Molecular Research Center, Cincinnati, OH) according to the manufacturer's protocol (7) . Following extraction, mRNAs were reverse transcribed using M-MLV reverse transcriptase (Gibco BRL, Gaithersburg, MD) and an oligo(dT) primer (Promega, Madision, WI) (4). RNA yield and amount of RNA used in reverse transcription reactions was previously described (6) . RNase-free water (Gibco BRL) and RNasin (Promega) were used in all steps involving RNA. Gene expression was determined using previously reported methods for competitive RT-PCR (6, 8, 9) . PCR reactions were cycled 35 times in a Rapidcycler (Idaho Technology, Idaho Falls, ID) in the presence of two types of controls. First, a housekeeping gene (β-actin) was co-amplified along with the target gene to control for the amount of cDNA included in the reaction. Second, known amounts of cDNA competitive templates (CTs) were included for both the target genes and β-actin to control for the loss of predictable exponential amplification with increasing cycles (8) (9) (10) . In these experiments, the concentration of the CTs in each PCR reaction was 10 -14 M for β-actin and 10 -17 M for each of the other genes. CTs were synthesized according to previously described methods (8, 11) using the forward and CT primers listed in Table II . Primers for synthesizing CTs and for amplification of native and CT sequences were chosen using Oligo software (National Biosciences, Plymouth, MN). Sequences for CYP2A6 (GenBank accession nos M33318 and M33316) (12) and CYP2E1 (J02843) (13) were retrieved from GenBank. Table II lists primer sequences and product lengths for both native and CT PCR products. Primers for β-actin and CYP2E1 have been reported previously (4, 6 ). Due to the high level of homology between CYP2A6 and CYP2A7 transcripts (96%) (14) , it was not possible to design primers specific for CYP2A6 that were suitable for PCR amplification under our standard conditions. Primers chosen for CYP2A6 amplification have identical sequence homology with CYP2A7. Digestion with PstI (for which there is a restriction site within the region of CYP2A6 amplified by these primers, but not in CYP2A7) and NdeI (which cuts CYP2A7 but not CYP2A6) confirmed that the product amplified from the BECs of three subjects was CYP2A6 and not CYP2A7 (data not shown). Due to the relatively large amounts of cDNA needed to perform this digestion and be able to visualize the restriction fragments on a gel, it was not possible to confirm these results in all subjects.
In each experiment, a single sample was evaluated for expression of CYP2A6 and CYP2E1. The same CT mixture stock was used for all of the PCR experiments reported here. Thus, the initial number of β-actin CT molecules (60 000 molecules) relative to the initial number of each of the target gene (CYP2A6 and CYP2E1) CT molecules (60 molecules) was the same in each PCR reaction. A master mix sufficient for the planned number of PCR reactions was prepared that contained every component except the primers. The components of the master mix were 0.2 mM dNTPs (Promega), 1/10 vol 10ϫ PCR buffer (Idaho Technology), water, 0.5 U/reaction Taq polymerase (Promega) and 1/10 vol 10ϫ CT solution. The 10ϫ CT solution contained 10 -13 M β-actin CT and 10 -16 M CYP2A6 and CYP2E1 CTs. The gene to be amplified in each reaction was specified by the primers included in each reaction tube, aliquoted separately from the master mix. After 9 µl master mix was aliquoted into each PCR reaction tube, 1 µl 10ϫ primer solution for β-actin, CYP2A6 or CYP2E1 was aliquoted into the appropriately labeled tube. We have compared this method with one where both the housekeeping and target gene were amplified in the same tube and found that there was no significant difference in the results obtained (8) . Whenever sufficient cDNA was available, triplicate experiments were performed.
Following amplification, products were electrophoresed on 4% agarose gels (3:1 NuSieve:SeaKem) containing 0.05 µg/ ml ethidium bromide. Gels were visualized with a Foto/Eclipse image analysis system (Fotodyne, Hartland, WI) and digital images were saved on a Power Mac 7100/66 computer (4). A representative gel is shown in Figure 1 . Collage software (Fotodyne) was employed for densitometric analysis. Quantification of expression of the target genes was determined in the following way. First, the ratio of β-actin gene native template (NT) to CT PCR product was calculated. Since the initial number of β-actin gene CT molecules was known (60 000 molecules in a 10 µl reaction containing 10 -14 M CT), the NT:CT ratio multiplied by 60 000 molecules provided the initial number of β-actin gene native cDNA molecules in Fig. 2 . Amplification efficiencies of the native and CT PCR products for β-actin and CYP2A6. For each gene, an assumption of the initial number of native molecules in a particular cDNA was made based on previous experiments. cDNA was placed in a PCR master mix and then transferred to individual reaction tubes containing differing numbers of CT molecules. The ratio of the assumed initial number of native molecules to the known initial number of CT molecules prior to amplification is plotted along the x-axis. The ratio of the calculated number of native molecules to the known number of CT molecules after PCR amplification is plotted along the y-axis. Since each graph is linear and the slopes are~1, the efficiency of amplification for the native PCR products and the corresponding PCR CT products are approximately equal. the reaction. Using the NT:CT PCR product ratio to calculate the initial number of NT molecules was possible because there was a linear relationship between the initial NT:CT ratio and the PCR product NT:CT ratio (Figure 2) . Second, the initial number of CYP2A6 gene NT molecules was calculated in the same way. Third, to correct for loading differences, the calculated initial number of target gene NT molecules was divided by the calculated initial number of β-actin native molecules. When a heterodimer was quantifiable, we added half the molecules in this band to the native molecules and half to the CT molecules (8, 9) . Since ethidium bromide staining is affected by both the number of molecules present in the band and the size of the molecules, the pixel value of the native band was corrected for size prior to making these calculations, so that comparison with the pixel value of the CT band would be based only on the relative number of molecules (8, 9) .
A two-factor Friedman test was used to determine statistical differences between groups and individuals. The factors used were 'subject' and 'smoking history' (either smoker or nonsmoker). A second two-factor Friedman test was run with the factors 'subject' and 'sex'. Differences were considered statistically significant at P Ͻ 0.05 in a two-tailed test.
CYP2A6 was quantifiable in 12/12 non-smokers with a mean expression of 740 mRNA/10 6 β-actin mRNA and in 6/8 smokers with a mean expression of 260 mRNA/10 6 β-actin mRNA (Table III) . The two remaining smokers expressed CYP2A6 at levels below our limit for quantification (10 mRNA/10 6 β-actin mRNA). There was significant (P Ͻ 0.05) inter-individual variation in CYP2A6 expression among both smokers and non-smokers. There was no significant difference in CYP2A6 expression between males and females (P ϭ 0.99). A limited amount of cDNA from cases 12 and 19 was available. Consequently, the concentration of the cDNA in the reaction could not be increased in an effort to visualize CYP2A6 native PCR product. Therefore, in subjects 12 and 19 CYP2A6 expression could be high or low relative to the quantified cases and no conclusion could be drawn on these subjects. The level of CYP2A6 expression (means of two to three replicates) for each volunteer is presented in Table III along with CYP2B6 expression data, some of which has been published previously (6) .
There was significantly less CYP2A6 expression in smokers than in non-smokers (P Ͻ 0.05) (Table III) . Since PAHs in cigarette smoke are thought to induce CYP1A1 and CYP1B1 expression in BECs of smokers (6) , it was hypothesized that levels of CYP2A6 would increase in smokers as a result of nitrosamine exposure. However, the data reported here suggest that smoking reduces CYP2A6 mRNA expression in BECs.
The mechanisms and effects of this reduction require further investigation.
We have quantified expression of 20 other XMEs in smokers and non-smokers and have not observed a smoking-associated reduction in expression for any of them. Shimada and Guengerich (15) reported that cigarette smoke contains potent inhibitors of CYP1A2. These inhibitors affect the enzymatic capacity of CYP1A2, but their affect on transcription of CYP1A2 is not known. Others have reported a negative regulatory system for expression of CYP1A1 (16), but it has not been reported thus far whether this system responds to cigarette smoke components. Thus, it is possible that components of cigarette smoke inhibit expression of CYP2A6. One way to investigate this hypothesis would be to evaluate effects of cigarette smoke condensate on cells transiently transfected with a reporter gene plasmid controled by the CYP2A6 regulatory region.
CYP2E1 expression was observed in the BECs of 9/20 volunteers (Table III) . CYP2E1 NT was observed only in the absence of CT in all cases and, therefore, was not quantifiable. If even the lowest detectable level of CT (10 -17 M) was included in the reaction, it out-competed the NT for primers and the fluorescent signal from any NT PCR product was below our limit of detection. Thus, expression of CYP2E1 is presented in Table III as present or not (ϩ/-). Since no housekeeping gene or CYP2E1 CT was amplified in the reactions where a CYP2E1 NT was seen, we do not know how much cDNA was included in the reaction and, therefore, we cannot conclude that subjects that were positive for CYP2E1 expressed more CYP2E1 than those that were negative for CYP2E1.
Because CYP2E1 was expressed at low levels compared with CYP2A6, we hypothesize that it plays only a minor role in nitrosamine oxidation in BECs. Furthermore, while CYP3A4/3A5 is primarily responsible for hepatic aflatoxin B1 metabolism, since it is not expressed in the BECs of these subjects (6; unpublished data), CYP2A6 is likely to perform this function in BECs. The inter-individual variation in CYP2A6 expression reported here may be especially important in regions where aflatoxin B1 is prevalent and for workers who are occupationally exposed through inhalation of grain dust (17) .
Due to the small number of cells available by bronchial brush biopsy, it was not possible to measure protein and/or enzyme activity levels in this study. However, in other studies there has generally been a good correlation between XME protein and enzyme activity levels and mRNA levels, including CYP1A1 (6, 18) , NADPH oxidoreductase (6) and glutathione S-transferase P1 (19) . More relevant to this study, CYP2A6 RNA levels correlated with enzyme activities in 11 of 12 human liver samples (12) . Based on these studies, it is reasonable to expect that the mRNA expression levels for CYP2A6 and CYP2E1 in human BECs reported here closely approximate the enzyme activities in the same samples, although this has not been assessed in BECs.
It is likely that risk for bronchogenic carcinoma following exposure to xenobiotic carcinogens will depend in part on relative expression of numerous phase I and phase II XME genes. For example, although CYP2A6 is expressed at relatively high levels in subjects 1 and 6, their risk for bronchogenic carcinoma from nitrosamines may be quite different, due to markedly different levels of CYP2B6 expression (Table III) .
Based on the data reported here, it is hypothesized that inter-individual variation in constitutive and/or cigarette smoke-reduced expression of CYP2A6 may contribute to inter-individual variation in risk for bronchogenic carcinoma. In addition, while several CYP enzymes are known to metabolically activate nitrosamines, we conclude that CYP2A6 is the most likely CYP enzyme to affect risk of nitrosamine exposure-associated bronchogenic carcinoma due to its relatively high mRNA expression in BECs and its high specificity for nitrosamine substrates (4).
